3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma
3
Breast Neoplasms
3
Recurrence
2
Ovarian Neoplasms
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, B-Cell, Marginal Zone
2
Carcinoma, Non-Small-Cell Lung
2
Waldenstrom Macroglobulinemia
1
Uveal Melanoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Leukemia-Lymphoma, Adult T-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Hodgkin Disease
1
Glioblastoma
1
Eye Neoplasms
1
Carcinoma, Transitional Cell
1
Adenocarcinoma
1
Interventions
pembrolizumab
38
Gemcitabine
29
Nivolumab
20
Cisplatin
19
atezolizumab
15
avelumab
14
Docetaxel
13
enfortumab vedotin
11
Carboplatin
10
durvalumab
9
Magnetic Resonance Spectroscopy
9
Ipilimumab
8
Paclitaxel
7
Pemetrexed
6
toripalimab
5
cabozantinib
5
Fluorodeoxyglucose F18
5
sacituzumab govitecan
4
cabazitaxel
4
Taxes
4
vinflunine
3
tremelimumab
3
pemigatinib
3
X-Rays
3
Standard of Care
3
Specimen Handling
3
Radiotherapy
3
Mitomycin
3
Immunotherapy
3
Immunoglobulin G
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Transitional Cell
×
belinostat
×
Clear all
NCT05154994
2026-05-07
RESOLVE
University of Utah
Phase 1
Active not recruiting
9 enrolled